Bio Essence Corp (BIOE) stock

BIOEOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/30

$0.42+0.03 (+7.72%)

Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –

Bio Essence ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Bio Essence's ebitda for the twelve months ending Sep 30, 2026 was $1.64M. For fiscal 2025 it was $900.25K. The highest annual figure on record is $900.25K in fiscal 2025.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$900.25K	–
FY2024	Dec 31, 2024	-$458.53K	–
FY2023	Dec 31, 2023	-$340.80K	–
FY2022	Dec 31, 2022	-$496.63K	–
FY2021	Dec 31, 2021	-$821.73K	–
FY2020	Dec 31, 2020	-$799.29K	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$15.88K	+10.9%
Q2 FY2026	Jun 30, 2026	$382.89K	+524.8%
Q1 FY2026	Mar 31, 2026	$215.85K	–
Q4 FY2025	Dec 31, 2025	$1.03M	+26234.7%
Q3 FY2025	Sep 30, 2025	$14.31K	–
Q2 FY2025	Jun 30, 2025	$61.28K	–
Q1 FY2025	Mar 31, 2025	-$205.03K	–
Q4 FY2024	Dec 31, 2024	$3.91K	–
Q3 FY2024	Sep 30, 2024	-$146.39K	–
Q2 FY2024	Jun 30, 2024	-$164.72K	–
Q1 FY2024	Mar 31, 2024	-$151.33K	–
Q4 FY2023	Dec 31, 2023	-$197.92K	-587.4%
Q3 FY2023	Sep 30, 2023	-$80.22K	–
Q2 FY2023	Jun 30, 2023	-$40.83K	–
Q1 FY2023	Mar 31, 2023	-$21.83K	–
Q4 FY2022	Dec 31, 2022	$40.60K	–
Q3 FY2022	Sep 30, 2022	-$177.28K	–
Q2 FY2022	Jun 30, 2022	-$144.39K	–
Q1 FY2022	Mar 31, 2022	-$215.56K	–
Q4 FY2021	Dec 31, 2021	-$188.97K	–
Q3 FY2021	Sep 30, 2021	-$184.24K	–
Q2 FY2021	Jun 30, 2021	-$252.50K	–
Q1 FY2021	Mar 31, 2021	-$196.02K	–
Q4 FY2020	Dec 31, 2020	-$320.36K	–
Q3 FY2020	Sep 30, 2020	-$178.99K	–
Q2 FY2020	Jun 30, 2020	-$187.93K	–
Q1 FY2020	Mar 31, 2020	-$112.01K	–